Evidence map›Paper›PMID 29395336›Full record

ArticleKidney international2018

Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria.

Ruhul Amin, John Asplin, Daniel Jung, Mohamed Bashir, Altayeb Alshaikh, Sireesha Ratakonda, Sapna Sharma, Sohee Jeon, Ignacio Granja, Dietrich Matern and 1 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Metabolic changes in kidney stone disease.Frontiers in immunology · 2023
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Oxalate homeostasis.Nature reviews. Nephrology · 2023
    Review
  11. Review
  12. Article
  13. Nephrolithiasis: A Red Flag for Cardiovascular Risk.Journal of clinical medicine · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ruhul AminDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
John AsplinLitholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois, USA.
Daniel JungDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Mohamed BashirDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Altayeb AlshaikhDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Sireesha RatakondaDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Sapna SharmaDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Sohee JeonDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.
Ignacio GranjaLitholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois, USA.
Dietrich MaternDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Hatim HassanDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA. Electronic address: hhassan@medicine.bsd.uchicago.edu.
University of Chicago · USLabCorp (United States) · USLink Foundation · USMayo Clinic · US

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI CHANG, EUGENE B · 1990 to 2025
$29.8M
Calcium Oxalate Kidney Stones: Pathogenesis of Obesity-associated HyperoxaluriaR01DK101643 · NIDDK · UNIVERSITY OF CHICAGO · PI HASSAN, HATIM A · 2014 to 2018
$1.7M
NIDDK NIH HHS P30 DK042086NIDDK NIH HHS R01 DK101643
6 · The paper itself

Abstract

Most kidney stones are composed of calcium oxalate, and minor changes in urine oxalate affect the stone risk. Obesity is a risk factor for kidney stones and a positive correlation of unknown etiology between increased body size, and elevated urinary oxalate excretion has been reported. Here, we used obese ob/ob (ob) mice to elucidate the pathogenesis of obesity-associated hyperoxaluria. These ob mice have significant hyperoxaluria (3.3-fold) compared with control mice, which is not due to overeating as shown by pair-feeding studies. Dietary oxalate removal greatly ameliorated this hyperoxaluria, confirming that it is largely enteric in origin. Transporter SLC26A6 (A6) plays an essential role in active transcellular intestinal oxalate secretion, and ob mice have significantly reduced jejunal A6 mRNA (- 80%) and total protein (- 62%) expression. While net oxalate secretion was observed in control jejunal tissues mounted in Ussing chambers, net absorption was seen in ob tissues, due to significantly reduced secretion. We hypothesized that the obesity-associated increase in intestinal and systemic inflammation, as reflected by elevated proinflammatory cytokines, suppresses A6-mediated intestinal oxalate secretion and contributes to obesity-associated hyperoxaluria. Indeed, proinflammatory cytokines (elevated in ob mice) significantly decreased intestinal oxalate transport in vitro by reducing A6 mRNA and total protein expression. Proinflammatory cytokines also significantly reduced active mouse jejunal oxalate secretion, converting oxalate transport from net secretion in vehicle-treated tissues to net absorption in proinflammatory cytokines-treated tissues. Thus, reduced active intestinal oxalate secretion, likely secondary to local and systemic inflammation, contributes to the pathogenesis of obesity-associated hyperoxaluria. Hence, proinflammatory cytokines represent potential therapeutic targets.

Indexed as

AnimalsAntiportersCaco-2 CellsCytokinesDisease Models, AnimalDown-RegulationHumansHyperoxaluriaInflammation MediatorsIntestinal AbsorptionIntestinal SecretionsJejunumMaleMice, Inbred BALB CMice, Inbred C57BLObesityAntiportersCytokinesInflammation MediatorsOxalatesSLC26A6 protein, humanSlc26a6 protein, mouseSulfate Transportershyperoxaluriainflammationintestinal oxalate secretionobesitySLC26A6

Identifiers

PMID29395336
PMCPMC5963707
OpenAlexW2786001144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.